Meeting
2017 ASCO Annual Meeting
Phase III study of NEPA, a fixed combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV).
Authors
Li Zhang
Sun Yat-Sen University Cancer Center, Guangzhou, China
Li Zhang , Shun Lu , Ji Feng Feng , Arunee Dechaphunkul , Salvatore Chessari , Corinna Lanzarotti , Karin Jordan , Matti S. Aapro
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Palliative Care and Symptom Management
Citation
J Clin Oncol 35, 2017 (suppl; abstr 10090)
DOI
10.1200/JCO.2017.35.15_suppl.10090
Abstract #
10090
Poster Bd #
79
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Efficacy of NEPA, a novel combination of netupitant (NETU) and palonosetron (PALO), for prevention of chemotherapy-induced nausea and vomiting (CINV) following highly emetogenic chemotherapy (HEC).
First Author: Paul Joseph Hesketh
Poster
2017 Palliative and Supportive Care in Oncology Symposium
Evaluation of daily breakthrough chemotherapy-induced nausea and vomiting (CINV) rates in a phase III study of NEPA versus an aprepitant (APR)/granisetron (GRAN) regimen.
First Author: Eric Roeland
Poster
2016 ASCO Annual Meeting
Placebo-controlled phase III study comparing dexamethasone on day 1 to on day 1-3 with NK1 receptor antagonist and palonosetoron in high emetogenic chemotherapy.
First Author: Kunihiro Matsuzaki
Poster
2014 Genitourinary Cancers Symposium
Palonostron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting (CINV) during gemcitabine/cisplatin (GC) in urothelial cancer (UC) patients: A multi-institutional retrospective study in Japan.
First Author: Hiroshi Kitamura